Seeking Alpha
 

Accretive Health, Inc. (AH)

- NYSE
AH is defunct.
  • Mar. 12, 2014, 9:34 AM
    • Accretive Health (AH) is facing delistment from the NYSE before markets open on Monday after saying that it expects to miss a March 19 deadline to file restated financial reports.
    • In March last year, Accretive Health's audit committee ordered the company to restate results due to errors related to the timing of revenue recognition.
    • While Accretive Health works on its earnings, it will trade over the counter.
    • Shares are -12.1% premarket. (PR)
    | Comment!
  • Nov. 13, 2013, 5:41 PM
    • Top Gainers, as of 5:15 p.m.: YUME +21.8%. TCX +12.3%. BORN +6.8%. NVAX +3.1%. TRLA +2.7%.
    • Top Losers, as of 5:15 p.m.: PRCP -25.5%. MM -15.0%. CSCO -9.8%. AH -3.9%. TXTR -3.9%.
    | Comment!
  • Nov. 13, 2013, 4:56 PM
    • Accretive Health (AH) -4% AH after updating the status of its ongoing restatement of financial results.
    • Net patient revenue under management declined between the end of 2011 and the end of Q3 2013, driven by client losses in 2012 and early 2013, and results also were hurt by operational and financial performance at one of the company's newer clients that were significantly below expectations in Q4 2012 but are rebounding in 2013.
    • Also, AH appoints two new board members and authorizes a $50M share repurchase program.
    | Comment!
  • Aug. 27, 2013, 11:21 AM
    • Accretive Health (AH -4%) slips after being downgraded to Perform by Oppenheimer.
    • Price target information was not available.
    • Yesterday, the company announced a shift in its financial leadership, appointing Sean Orr as its new chief financial officer and treasurer, replacing its current CFO, John Staton.
    | Comment!
  • Feb. 27, 2013, 12:55 PM
    Midday top 10 gainers: ZGNX +39%. UNXL +24%. FSGI +21%. GWRE +18%. ELMD +16%. PDCE +14%. OPTR +13%. DLTR +12%. END +11%. SHI +11%.
    Midday top 10 losers: AH -26%. CBB -23%. AMBO -22%. RNIN -21%. CBMX -19%. XWES -19%. FSLR -16%. CMGE -15%. CRMB -13%. PRPH -12%.
    | Comment!
  • Feb. 27, 2013, 8:33 AM
    Accretive Health (AH) plummets 30% after saying yesterday that its postponing its Q4 and FY earnings results. Raymond James suspends its rating, saying: "No visibility into future results, and are left with more questions than answers."
    | Comment!
  • Feb. 26, 2013, 5:51 PM
    After-hours top gainers, as of 5:15 p.m.: GWRE +9%. BGFV +8%. UVXY +5%. ZAGG +5%. TVIX +4%.
    After-hours top losers: FSLR -10%. AH -10%. MERU -9%. QCOR -6%. SPWR -5%.
    | 3 Comments
  • Feb. 26, 2013, 5:39 PM
    Accretive Health (AH) says it will postpone the release of its financial results for Q4 and FY12, as well as its previously announced investor conference call scheduled for February 27. The company is reviewing the manner in which it recognizes revenue for its revenue cycle management agreements, and based on information available to date, if a change becomes necessary, it may be required to restate prior-period financial statements. Shares -9.6% AH.
    | Comment!
  • Jan. 16, 2013, 12:32 PM
    Accretive Health (AH +1.1%) gains after Raymond James initiated the stock with a Strong Buy earlier today and a $16.00 price target. The firm notes four bullish components to AH's story: a shift from an information technology focus to to revenue cycle; a differentiated infused management model; margin expansion potential; and expectations for multiple expansion with its Minnesota litigation in the rearview mirror.
    | Comment!
  • Jul. 31, 2012, 9:10 AM
    Premarket gainers: AH +32%. CRUS +21%. CIE +16%. LQDT +14%. KLIC +13%. ATPG +12%. ZLCS +9%. HLF +7%. VLO +6%. NOK +6%.
    Losers: RLD -25%. COH -16%. DNDN -15%. HUM -10%. STX -8%. OCZ -8%. TWGP -7%. AMRN -5%. MMR -5%.
    | Comment!
  • Jul. 5, 2012, 9:29 AM
    Accretive Health (AH) +4.1% premarket following word late Tuesday that the healthcare revenue manager expects to reach a new five-year deal with Ascension Health by month’s end. Baird believes the deal, though “largely expected," removes a longstanding overhang on AH shares; Oppenheimer reiterates its Outperform rating.
    | Comment!
  • May 31, 2012, 2:00 PM
    The worst has past for Accretive Health (AH +2.5%), says Oppenheimer. The firm says that after attending Senator Franken's hearing on the charges against the company, it's confident that the more egregious charges are baseless. The firm thinks that the lack of new evidence indicates that the worst headline risk has passed.
    | 1 Comment
  • May 29, 2012, 2:24 PM
    Accretive Health (AH +4.9%) pops on an upgrade to Outperform at Cowen. The firm says its valuation adequately reflects long-term concerns and sees a potential positive catalysts from a possible settlement sometime this year.
    | Comment!
  • May 15, 2012, 3:37 PM
    Accretive Health (AH +3.7%) says prominent health care and policy leaders have agreed to convene to develop a process for implementing national standards for how hospitals and other providers interact with patients regarding their financial obligations. The standards will aim to cover expected charges, available resources, counseling, billing and payment procedures regardless of the ability to pay.
    | Comment!
  • May 15, 2012, 1:32 PM
    Shares of Accretive Health (AH +4.4%) bounce after the company submits a 29-page reply to questions raised by Senator Al Franken after Minnesota's AG alleged that AH used potentially illegal tactics to collect payments from patients at a Minnesota health facility. In its reply the company insisted it did not violate any federal laws related to patient privacy or debt collection and said it "appreciates the opportunity to set the record straight."
    | 1 Comment
  • May 1, 2012, 1:46 PM
    Accretive Health (AH -6.5%) slips after being downgraded to Neutral earlier today at UBS, citing uncertainty over recent investigations and their impact on its customer base, plus other possible EMTALA violations. The firm also cuts its price target cut to $11 from $29.
    | Comment!
Visit Seeking Alpha's
Company Description
Accretive Health, Inc. is providers of services that help healthcare providers generate sustainable improvements in their operating margins and healthcare quality while also enhancing patient, physician and staff satisfaction.
Sector: Services
Country: United States